Liquidia Corporation (NASDAQ:LQDA) announced Thursday a lawsuit challenging the recent FDA decision to grant a three-year ...
Despite the unfavorable ruling for Liquidia, the regulatory exclusivity period for Tyvaso DPI is still set to expire on May 23, 2025. Additionally, United Therapeutics had filed a cross claim in ...
Hosted on MSN17d
United Therapeutics Stock Down Despite Q4 Earnings & Sales BeatUnited Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high ...
MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s ...
Total Tyvaso revenues grew by 19 percent to $415.9 million in the fourth quarter of 2024, compared to $350.6 million in the fourth quarter of 2023. This growth was primarily driven by growth in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results